sorafenib has been researched along with 5-(4-methoxybenzylidene)thiazolidine-2,4-dione in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (5-(4-methoxybenzylidene)thiazolidine-2,4-dione) | Trials (5-(4-methoxybenzylidene)thiazolidine-2,4-dione) | Recent Studies (post-2010) (5-(4-methoxybenzylidene)thiazolidine-2,4-dione) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 14 | 0 | 9 |
| Protein | Taxonomy | sorafenib (IC50) | 5-(4-methoxybenzylidene)thiazolidine-2,4-dione (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 3.5 | |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | 1.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alswah, M; El-Adl, K; Nasser, M; Sakr, H; Shoman, FMA | 1 |
1 other study(ies) available for sorafenib and 5-(4-methoxybenzylidene)thiazolidine-2,4-dione
| Article | Year |
|---|---|
5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
Topics: Antineoplastic Agents; Doxorubicin; HCT116 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship; Thiazolidinediones; Vascular Endothelial Growth Factor Receptor-2 | 2020 |